NO20075412L - Fremgangsmater og preparater til modulering av hyperstabilisert C-MET - Google Patents
Fremgangsmater og preparater til modulering av hyperstabilisert C-METInfo
- Publication number
- NO20075412L NO20075412L NO20075412A NO20075412A NO20075412L NO 20075412 L NO20075412 L NO 20075412L NO 20075412 A NO20075412 A NO 20075412A NO 20075412 A NO20075412 A NO 20075412A NO 20075412 L NO20075412 L NO 20075412L
- Authority
- NO
- Norway
- Prior art keywords
- met
- hyper
- modulating
- stabilized
- preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66548205P | 2005-03-25 | 2005-03-25 | |
PCT/US2006/010850 WO2006104911A2 (en) | 2005-03-25 | 2006-03-24 | Methods and compositions for modulating hyperstabilized c-met |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075412L true NO20075412L (no) | 2007-12-21 |
Family
ID=37053941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075412A NO20075412L (no) | 2005-03-25 | 2007-10-24 | Fremgangsmater og preparater til modulering av hyperstabilisert C-MET |
Country Status (18)
Country | Link |
---|---|
US (2) | US7615529B2 (ja) |
EP (1) | EP1868648B1 (ja) |
JP (2) | JP2008535821A (ja) |
KR (1) | KR20080000613A (ja) |
CN (1) | CN101184506B (ja) |
AU (1) | AU2006229989B2 (ja) |
BR (1) | BRPI0611468A2 (ja) |
CA (1) | CA2599988A1 (ja) |
ES (1) | ES2539790T3 (ja) |
HK (1) | HK1109075A1 (ja) |
IL (1) | IL185708A (ja) |
MX (1) | MX2007011652A (ja) |
NO (1) | NO20075412L (ja) |
NZ (1) | NZ561211A (ja) |
RU (1) | RU2404193C2 (ja) |
SG (1) | SG159547A1 (ja) |
WO (1) | WO2006104911A2 (ja) |
ZA (1) | ZA200707953B (ja) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080000613A (ko) * | 2005-03-25 | 2008-01-02 | 제넨테크, 인크. | 과안정화된 c-met의 조절을 위한 방법 및 조성물 |
AR070861A1 (es) * | 2008-03-06 | 2010-05-12 | Genentech Inc | Uso de terapia de combinacion con antagonistas de c-met y egfr |
EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
EP2417159A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-3/anti-c-met antibodies |
CN102361883A (zh) * | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-1/抗-c-Met抗体 |
CN106188295A (zh) | 2009-04-20 | 2016-12-07 | 牛津生物疗法有限公司 | 特异于钙粘素‑17的抗体 |
KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
BR112012010153B1 (pt) * | 2009-11-05 | 2022-05-03 | Genentech, Inc | Método de produção de um anticorpo |
WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
WO2012054084A2 (en) * | 2010-10-20 | 2012-04-26 | Oxford Biotherapeutics Ltd. | Antibodies |
US20130004484A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
US9201074B2 (en) | 2011-09-20 | 2015-12-01 | Eli Lilly And Company | Anti-c-Met antibodies |
WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
JP2014533700A (ja) * | 2011-11-21 | 2014-12-15 | ジェネンテック, インコーポレイテッド | 抗c−MET抗体の精製 |
US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
PL2766048T3 (pl) | 2012-10-12 | 2015-05-29 | Medimmune Ltd | Pirolobenzodiazepiny i ich koniugaty |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
AU2014225661A1 (en) | 2013-03-06 | 2015-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-c-Met tandem Fc bispecific antibodies |
US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
CA2941687A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
BR112017005202A2 (pt) | 2014-09-16 | 2017-12-12 | Symphogen As | anticorpos anti-met e composições |
GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
US20180057595A1 (en) | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
EP3778643A1 (en) | 2016-09-14 | 2021-02-17 | AbbVie Biotherapeutics Inc. | Pharmaceutical uses of anti-pd-1(cd279) antibodies |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
CN113286616A (zh) | 2018-05-23 | 2021-08-20 | Adc治疗有限公司 | 分子佐剂 |
KR20210044207A (ko) | 2018-07-15 | 2021-04-22 | 이노치안 바이오파마, 인코포레이티드 | 암 치료를 위한 재조합 수지상 세포를 사용하는 방법 및 조성물 |
KR20210132117A (ko) | 2019-02-26 | 2021-11-03 | 얀센 바이오테크 인코포레이티드 | 이중특이성 항-EGFR/c-Met 항체를 사용한 병용 요법 및 환자 계층화 |
WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
CN114340684A (zh) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
CN114478788A (zh) | 2020-11-11 | 2022-05-13 | 高新 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
EP2014772A3 (en) | 1996-04-05 | 2009-05-27 | Antonio Giordano | Method for the diagnosis and prognosis of cancer |
DK0922102T3 (da) | 1996-07-03 | 2010-08-16 | Genentech Inc | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
KR101148657B1 (ko) * | 2003-06-06 | 2012-07-05 | 제넨테크, 인크. | Hgf 베타 쇄와 c-met 사이의 상호작용의 변조 |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
EP2336178A1 (en) * | 2003-12-11 | 2011-06-22 | Genentech, Inc. | Methods and compositions for inhibiting C-Met dimerization and activation |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
RU2007139516A (ru) | 2005-03-25 | 2009-04-27 | Дженентек, Инк. (Us) | Мутации с-мет при раке легких |
KR20080000613A (ko) | 2005-03-25 | 2008-01-02 | 제넨테크, 인크. | 과안정화된 c-met의 조절을 위한 방법 및 조성물 |
-
2006
- 2006-03-24 KR KR1020077024503A patent/KR20080000613A/ko not_active Application Discontinuation
- 2006-03-24 EP EP06748671.2A patent/EP1868648B1/en active Active
- 2006-03-24 WO PCT/US2006/010850 patent/WO2006104911A2/en active Application Filing
- 2006-03-24 CA CA002599988A patent/CA2599988A1/en not_active Abandoned
- 2006-03-24 CN CN2006800183951A patent/CN101184506B/zh active Active
- 2006-03-24 AU AU2006229989A patent/AU2006229989B2/en active Active
- 2006-03-24 SG SG201000940-5A patent/SG159547A1/en unknown
- 2006-03-24 BR BRPI0611468-7A patent/BRPI0611468A2/pt not_active Application Discontinuation
- 2006-03-24 NZ NZ561211A patent/NZ561211A/en unknown
- 2006-03-24 RU RU2007139452/10A patent/RU2404193C2/ru active
- 2006-03-24 ES ES06748671.2T patent/ES2539790T3/es active Active
- 2006-03-24 US US11/388,757 patent/US7615529B2/en active Active
- 2006-03-24 JP JP2008503236A patent/JP2008535821A/ja active Pending
- 2006-03-24 MX MX2007011652A patent/MX2007011652A/es active IP Right Grant
- 2006-03-24 ZA ZA200707953A patent/ZA200707953B/xx unknown
-
2007
- 2007-09-04 IL IL185708A patent/IL185708A/en active IP Right Grant
- 2007-10-24 NO NO20075412A patent/NO20075412L/no not_active Application Discontinuation
-
2008
- 2008-02-18 HK HK08101720.7A patent/HK1109075A1/xx unknown
-
2009
- 2009-09-29 US US12/569,552 patent/US8536118B2/en active Active
-
2012
- 2012-05-22 JP JP2012116934A patent/JP2012232979A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2599988A1 (en) | 2006-10-05 |
CN101184506B (zh) | 2013-07-17 |
BRPI0611468A2 (pt) | 2010-09-08 |
CN101184506A (zh) | 2008-05-21 |
IL185708A (en) | 2014-11-30 |
AU2006229989A1 (en) | 2006-10-05 |
RU2007139452A (ru) | 2009-04-27 |
US20100028337A1 (en) | 2010-02-04 |
IL185708A0 (en) | 2008-01-06 |
HK1109075A1 (en) | 2008-05-30 |
ZA200707953B (en) | 2009-06-24 |
NZ561211A (en) | 2011-03-31 |
ES2539790T3 (es) | 2015-07-06 |
MX2007011652A (es) | 2007-11-14 |
EP1868648B1 (en) | 2015-04-15 |
US8536118B2 (en) | 2013-09-17 |
WO2006104911A2 (en) | 2006-10-05 |
RU2404193C2 (ru) | 2010-11-20 |
KR20080000613A (ko) | 2008-01-02 |
AU2006229989B2 (en) | 2012-02-02 |
US20060270594A1 (en) | 2006-11-30 |
SG159547A1 (en) | 2010-03-30 |
WO2006104911A3 (en) | 2007-02-22 |
JP2012232979A (ja) | 2012-11-29 |
JP2008535821A (ja) | 2008-09-04 |
EP1868648A2 (en) | 2007-12-26 |
US7615529B2 (en) | 2009-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075412L (no) | Fremgangsmater og preparater til modulering av hyperstabilisert C-MET | |
DK1877390T3 (da) | Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf | |
NO20083147L (no) | Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse | |
NO20075693L (no) | Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme | |
HK1117746A1 (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
EA200701918A1 (ru) | Белок липокалин | |
DK1636593T3 (da) | Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met | |
DK1682530T3 (da) | Pyrrolsubstituerede indoler som inhibitorer af PAI-1 | |
NO20075647L (no) | Kjemiske forbindelser | |
WO2008033408A3 (en) | Methods for identifying compounds that modulate cell signaling and methods employing such compounds | |
ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
HRP20080564T3 (en) | Dihydrotetrabenazines and pharmaceutical compositions containing them | |
NO20082191L (no) | Forbindelser | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
MEP35408A (en) | Tweak binding antibodies | |
NO20076413L (no) | Multisykliske forbindelser og fremgangsmater for deres anvendelse | |
DK1592786T3 (da) | Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE). | |
NO20081160L (no) | Benzimidazoltiofen forbindelser | |
DK1836169T3 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
NO20070908L (no) | Sammensmeltede ringheterocykelkinasemodulatorer | |
DE602006015215D1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
MX2007008723A (es) | Polipeptidos de yersinia spp y metodos de uso. | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
CR9637A (es) | Proteinas de enlace il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |